Fully hybrid partnering and investment conference for the lifesciences industry– 21st– 25th June
Cambridge, UK, 21st June 2021 Exonate is pleased to attend BioTrinity a highly regarded biopartnering & investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.
The 2021 event will be delivered in a true hybrid format, and will provide seamless LIVE interaction for delegates, who include early-stage and emerging biotech, medtech and digital health companies, big pharma executives, life sciences investors and service providers.
Dr. Catherine Beech, CEO and members of Exonate’s management team are available for meetings and contact can be made via Sarah Buchallet. sarah.buchallet@exonate.com.
-END-
Contacts:
Exonate Limited
Sarah Buchallet, Marketing
Catherine Beech, CEO Tel: +44 (0) 1223 734710
Email: info@exonate.com
About Exonate:
Exonate are using the mRNA blueprint as a therapeutic formula to instruct cells in how to treat diseases. Leveraging our expertise in the alternative mRNA splicing of Vascular Endothelial Growth Factor (VEGF) we have developed a pipeline of small molecule drugs for the treatment of patients with chronic diseases
Exonate’s lead compound, formulated to be delivered topically with eye drops, is now in Phase 1 clinical trials for the treatment of centre-involved diabetic macular oedema. The clinical trial is in collaboration with Janssen Pharmaceuticals, Inc., and built upon extensive pre-clinical work supported by previous investments. Having relocated to larger research labs at MediCity we are continuing our pre-clinical mRNA-targeting research focusing on ophthalmology and renal disease.